PEDIATRICS Vol. 45 No. 3 March 1970, pp. 488-504
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Namba, T.
Right arrow Articles by Grob, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Namba, T.
Right arrow Articles by Grob, D.

NEONATAL MYASTHENIA GRAVIS: REPORT OF TWO CASES AND REVIEW OF THE LITERATURE

Tatsuji Namba M.D., Ph.D.1, Stuart B. Brown M.D.1, and David Grob M.D.1

1 Department of Medicine and Division of Neurology, Maimonides Medical Center and State University of New York Downstate Medical Center, Brooklyn, New York

Two male infants with neonatal myasthenia gravis are described. The serum of one patient and his myasthenic mother had no neuromuscular blocking activity or antinuclear globulin. Striation binding globulin was positive in the serum of the mother, but not the infant. Eighty two collected patients are reviewed. Incidence was 12% of babies born to myasthenic mothers. Onset was within 72 hours of birth. Mean duration was 18 days and maximum was 47 days. Nine patients died, with a mean duration of 6 days and a maximum of 21 days. The remaining patients recovered without recurrence, except for recurrence at 2 years in one patient. Manifestations were feeding difficulty (87%), generalized weakness (69%), respiratory difficulty (65%), feeble cry (60%), and facial weakness (54%), including ptosis (15%). Pharmacologic tests with neostigmine or edrophonium were positive in 86%. Management consisted of anticholinesterase medication in 81% for a mean of 21 days and general care, particularly respiratory care. The mothers all had generalized myasthenia gravis. Four mothers did not receive anticholinesterase medication and nine had undergone thymectomy. Eleven mothers subsequently had a second affected child, and five mothers had a normal child. There was no relation of neonatal myasthenia to striation binding or antinuclear globulin in serum of mother or infant.

Submitted on July 7, 1969
Accepted on August 28, 1969




This article has been cited by other articles:


Home page
 J Child NeurolHome page
G. Ahlsten, A.-K. Lefvert, P.-O. Osterman, E. Stalberg, and J. Safwenberg
Follow-up Study of Muscle Function in Children of Mothers With Myasthenia Gravis During Pregnancy
J Child Neurol, July 1, 1992; 7(3): 264 - 269.
[Abstract] [PDF]

Home page
 J Child NeurolHome page
O. Papazian
Topical Review Article: Transient Neonatal Myasthenia Gravis
J Child Neurol, April 1, 1992; 7(2): 135 - 141.
[Abstract] [PDF]

Home page
 J Child NeurolHome page
J. Z. Heckmatt, M. Placzek, A. H. Thompson, V. Dubowitz, and G. Watson
An Unusual Case of Neonatal Myasthenia
J Child Neurol, January 1, 1987; 2(1): 63 - 66.
[Abstract] [PDF]

Home page
 ScienceHome page
R. R. Almon, C. G. Andrew, and S. H. Appel
Serum Globulin in Myasthenia Gravis: Inhibition of agr-Bungarotoxin Binding to Acetylcholine Receptors
Science, October 4, 1974; 186(4158): 55 - 57.
[Abstract] [PDF]